Article
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
The oncologist - 1 Oct 2020
Nakamura Atsushi, Tanaka Hisashi, Saito Ryota, Suzuki Aya, Harada Toshiyuki, Inoue Sumito, Yamada Toru, Nakagawa Taku, Jingu Daisuke, Sugawara Shunichi
Abstract excerpt
LESSONS LEARNED: Low-dose afatinib maintenance treatment among patients with EGFR-mutated NSCLC achieved long-time to treatment failure with fewer treatment-related AEs without detracting from the therapeutic efficacy. This modified regimen represents a practical usage that balances effectiveness and safety. BACKGROUND: Although afatinib is an effective therapy for patients with EGFR-mutated non-small cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.